Should HPV vaccination be mandatory?

Should we force drug therapy because patients might get the disease based on future behavior?

Joseph De Soto MD, PhD, Magnuson Clinical Center, Mammalian Genetics/Genetics of Disease and Development Branch, National Institute of Diabetes, Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Md desotoj@niddk.nih.gov

The news that Merck & Co. had developed a new quadrivalent vaccine (Gardasil) that was effective in targeting strains of human papillomavirus (HPV) that account for about 70% of today’s cervical cancers prompted many state legislators to run to the microphone and push for mandatory vaccination of our 9-year-old daughters. Indeed, the governor of Texas unilaterally mandated the vaccine for school-age girls. Yet, were they acting in the public’s best interests or pushing an agenda?

As clinicians, we know that a person is likely to either be infected or exposed to more than one subtype of the sexually transmitted form of the HPV virus. The Gardasil vaccine however, suppresses only a few specific HPV types. (This is also the case with Cervarix, a bivalent vaccine that GlaxoSmithKline is seeking regulatory approval for.) Hence, those subtypes not suppressed will obtain an evolutionary advantage. They will become more prevalent and dominant, though the vaccine will have no effect on them.

Additionally, according to the data presented to the FDA (and which I have reviewed), it is clear that:

1) there is no evidence that Merck’s vaccine works after 5 years.
2) two-thirds of those who had received the vaccine suffered from moderate to severe pain at the site of injection.
3) we do not know whether this vaccine will cause autoimmune and neurological problems, ie seizures, in the long term.
4) the risk for pelvic inflammatory disease, appendicitis, and gastroenteritis is at least doubled.
5) the vaccine has not been adequately tested in girls under age 16. (While the efficacy of the vaccine was assessed in 4 placebo-controlled phase II and III clinical studies, which evaluated women between the ages of 16 and 26 only, those under age 16 were excluded.)

Also disturbing: The researchers’ choice of placebo. The placebo was not necessarily an innocuous vehicle such as normal saline, but one containing aluminum that is well known for its neurotoxicity. This would suggest that the actual and potential toxicity of the vaccine is probably higher than we think.

Is it ethical?

Mandatory vaccination also raises ethical issues. Under current proposals, we are talking about forcing people to un-
undergo mandatory drug therapy (vaccination), when they have no disease, under the presumption that they might get a disease based on future behavior. This is medically unethical.

One might argue that we do have, as public policy, mandatory vaccinations for some infectious disorders such as mumps, measles, and rubella. This is true, in part under the idea of herd immunity, that is, if 97% to 98% of a population is immunized against a disease, the disease may be nearly eradicated. That argument, however, doesn’t hold in this case, as the HPV vaccine is an incomplete vaccine. Also, let’s not forget that men, who are not being asked to receive the vaccine, make up half of those infected with HPV. Thus, herd immunity will not develop.

**Cost is a consideration**

Let’s not overlook the financial implications of mandatory vaccination. The vaccine costs $120 a dose and must be administered three times, for a total cost of $360 a child. Now multiply this times every school age child in the country; this translates into billions of dollars. Add to that the fact that the vaccine may not be effective in the long term. So will booster shots at $120 be required?

All of this does not negate that the HPV vaccine does have value. We should, however, approach the idea of mandatory vaccination with caution.

**Disclosure**

No potential conflict of interest relevant to this article was reported.

The opinions and assertions contained herein are the private views of the author and not to be construed as official, or as reflecting the views of the National Institute of Diabetes, Digestive and Kidney Diseases, or the National Institutes of Health.

**Reference**


---

### Making sense of EVIDENCE-BASED MEDICINE RATINGS

**The Journal of Family Practice** provides Strength of Recommendation (SOR) ratings for key recommendations in many of its articles. SORs are based on the highest-quality of evidence available. The ratings are as follows:

- **A** Recommendation based on consistent and good-quality patient–oriented evidence.
- **B** Recommendation based on inconsistent or limited-quality patient-oriented evidence.
- **C** Recommendation based on consensus, usual practice, opinion, disease-oriented evidence, or case series for studies of diagnosis, treatment, prevention, or screening

**Levels of evidence** determine whether a study measuring patient-oriented outcomes is of good or limited quality, and whether the results are consistent or inconsistent between studies.

**Study quality**

1. Good-quality, patient-oriented evidence (eg, validated clinical decision rules, systematic reviews and meta-analyses of randomized controlled trials [RCTs] with consistent results, high-quality RCTs, or diagnostic cohort studies).
2. Lower-quality patient-oriented evidence (eg, unvalidated clinical decision rules, lower-quality clinical trials, retrospective cohort studies, case control studies, and case series).
3. Other evidence (eg, consensus guidelines, usual practice, opinion, case series for studies of diagnosis, treatment, prevention, or screening).

To learn more about SOR ratings and the Strength of Recommendation Taxonomy (SORT), point your browser to: [www.jfponline.com/Pages.asp?AID=1635](www.jfponline.com/Pages.asp?AID=1635)